Key Decisions and Approvals
The Board of Directors of Shukra Pharmaceuticals Limited, at its meeting held on August 14, 2026, approved:
- Change of company name from "Shukra Pharmaceuticals Limited" to "Shukra Medtech Limited" (or such other name as may be approved by authorities)
- Alteration and expansion of the existing Main Objects Clause of the Memorandum of Association to include medical technology activities
Business Expansion Details
The expansion enables the company to undertake activities in medical technology including:
- Development, manufacturing, processing, designing
- Research and development
- Distribution, marketing, trading
- Related activities in medical technology products, devices, equipment, systems and solutions
Approval Requirements
The changes are subject to:
- Approval of shareholders of the Company
- Receipt of requisite statutory and regulatory approvals
- Approvals under Companies Act, 2013
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 compliance
- Other applicable laws and regulations
Strategic Rationale
The proposed changes are intended to:
- Provide broader corporate identity
- Enable exploration of business opportunities in medical technology sector
- Complement existing pharmaceutical and healthcare-related activities
- Part of broader strategy to expand across healthcare and medical technology ecosystem
- Create opportunities for sustainable long-term growth
Financial Impact
Financial impact not quantified in the disclosure.